SonoThera
Financing Round
- Series B
SonoThera is developing the next generation of genetic medicines through its proprietary ultrasound-mediated, nonviral delivery platform. The company’s technology is designed to enable targeted delivery of diverse genetic payloads without size restrictions in a safe, non-invasive, and redosable manner, expanding the potential of genetic medicines to treat the root causes of disease.
View Website
Modality
- Genetic Medicine
Indications
- Circulatory & Metabolic Disease
- Other
Development Status
- Pre-Clinical